These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 38167329)
41. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Wehrli M; Maus MV Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161 [TBL] [Abstract][Full Text] [Related]
48. CAR T cells: Building on the CD19 paradigm. Globerson Levin A; Rivière I; Eshhar Z; Sadelain M Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410 [TBL] [Abstract][Full Text] [Related]
49. Synthetic therapeutic gene circuits in mammalian cells. Ye H; Fussenegger M FEBS Lett; 2014 Aug; 588(15):2537-44. PubMed ID: 24844435 [TBL] [Abstract][Full Text] [Related]
50. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Ruppel KE; Fricke S; Köhl U; Schmiedel D Front Immunol; 2022; 13():822298. PubMed ID: 35371071 [TBL] [Abstract][Full Text] [Related]
51. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Yu S; Yi M; Qin S; Wu K Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760 [TBL] [Abstract][Full Text] [Related]
52. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Shum T; Kruse RL; Rooney CM Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246 [TBL] [Abstract][Full Text] [Related]
53. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Zhang C; Hu Y; Xiao W; Tian Z Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335 [TBL] [Abstract][Full Text] [Related]
54. Biomaterials for chimeric antigen receptor T cell engineering. Niu H; Zhao P; Sun W Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403 [TBL] [Abstract][Full Text] [Related]
55. Synthetic Notch-Receptor-Mediated Transmission of a Transient Signal into Permanent Information via CRISPR/Cas9-Based Genome Editing. Sgodda M; Alfken S; Schambach A; Eggenschwiler R; Fidzinski P; Hummel M; Cantz T Cells; 2020 Aug; 9(9):. PubMed ID: 32825374 [TBL] [Abstract][Full Text] [Related]
56. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053 [TBL] [Abstract][Full Text] [Related]
57. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. Huang D; Miller M; Ashok B; Jain S; Peppas NA Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148 [TBL] [Abstract][Full Text] [Related]
58. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Morsut L; Roybal KT; Xiong X; Gordley RM; Coyle SM; Thomson M; Lim WA Cell; 2016 Feb; 164(4):780-91. PubMed ID: 26830878 [TBL] [Abstract][Full Text] [Related]
59. Advances in modular control of CAR-T therapy with adapter-mediated CARs. McCue AC; Yao Z; Kuhlman B Adv Drug Deliv Rev; 2022 Aug; 187():114358. PubMed ID: 35618140 [TBL] [Abstract][Full Text] [Related]
60. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Dimitri A; Herbst F; Fraietta JA Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]